PMID- 33882758
OWN - NLM
STAT- MEDLINE
DCOM- 20210826
LR  - 20210826
IS  - 1751-2441 (Electronic)
IS  - 1751-2433 (Linking)
VI  - 14
IP  - 7
DP  - 2021 Jul
TI  - Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease.
PG  - 837-852
LID - 10.1080/17512433.2021.1917374 [doi]
AB  - Introduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes 
      mellitus (T2DM) are significant non-communicable diseases that often affect 
      individuals concurrently. In individuals with both T2DM and NAFLD, there is 
      evidence that anti-diabetic therapies may demonstrate potential combined 
      beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A 
      PubMed and Google Scholar search was performed to find relevant literature. 
      Included studies focused on individuals with T2DM and NAFLD receiving 
      anti-diabetic treatments including bariatric surgery, insulin sensitizers, 
      incretin mimetics, and SGLT2 inhibitors. Additional articles highlight 
      investigational treatments.Expert opinion: In individuals with T2DM and NAFLD, 
      5-10% weight loss or bariatric surgery if unable to lose weight or maintain 
      weight loss are appropriate. GLP-1 receptor agonists and SGLT2 inhibitors result 
      in weight loss, appear safe and may provide beneficial hepatic outcomes. Whether 
      their effects are related to favorable weight changes or intrinsic hepatic 
      effects is unclear. Thiazolidinediones have advantageous anti-hyperglycemic and 
      hepatic effects but individuals must be monitored for weight gain and edema. 
      Metformin and DPP-4 inhibitor beneficial hepatic effects remain debated. There 
      are opportunities to standardize markers and imaging of NAFLD. Studies powered to 
      evaluate the possible cardiovascular benefits of anti-diabetic therapies in 
      individuals with T2DM and NAFLD are needed.
FAU - Lamos, Elizabeth M
AU  - Lamos EM
AD  - Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, 
      University of Maryland School of Medicine, Baltimore, MD, USA.
FAU - Kristan, Megan
AU  - Kristan M
AD  - Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, 
      University of Maryland School of Medicine, Baltimore, MD, USA.
FAU - Siamashvili, Maka
AU  - Siamashvili M
AD  - Department of Medicine, University of Maryland Medical Center, Baltimore, MD, 
      USA.
FAU - Davis, Stephen N
AU  - Davis SN
AD  - Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210422
PL  - England
TA  - Expert Rev Clin Pharmacol
JT  - Expert review of clinical pharmacology
JID - 101278296
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Animals
MH  - Bariatric Surgery/methods
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/physiopathology
OTO - NOTNLM
OT  - Bariatric surgery
OT  - Sodium-glucose cotransporter-2 inhibitors
OT  - Thiazolidinediones
OT  - diabetes mellitus
OT  - dipeptidyl-peptidase -4 inhibitors
OT  - metformin
OT  - nonalcoholic fatty liver disease
OT  - weight loss
EDAT- 2021/04/23 06:00
MHDA- 2021/08/27 06:00
CRDT- 2021/04/22 05:31
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/08/27 06:00 [medline]
PHST- 2021/04/22 05:31 [entrez]
AID - 10.1080/17512433.2021.1917374 [doi]
PST - ppublish
SO  - Expert Rev Clin Pharmacol. 2021 Jul;14(7):837-852. doi: 
      10.1080/17512433.2021.1917374. Epub 2021 Apr 22.